Comparing Topical 2-Deoxy-D-ribose Hydrogel and Minoxidil 5% Solution to Treat Mild to Moderate Androgenetic Alopecia in Adults Aged 18 to 50

What this Trial Is About

Researchers are evaluating the effectiveness and safety of a topical 2-Deoxy-D-ribose 2dDR hydrogel compared with topical minoxidil 5% solution in treating mild to moderate androgenetic alopecia AGA in adults aged 18 to 50 years. AGA is a common form of hair loss influenced by genetic and hormonal factors, leading to progressive hair thinning and follicle changes. The study aims to assess these treatments and explore how 2dDR may work by measuring vascular endothelial growth factor VEGF levels in scalp tissue. Sixty participants will be randomly assigned to one of two groups. One group will apply 1 gram of 2dDR hydrogel once daily to affected scalp areas for six months. The other group will apply minoxidil 5% solution for six months, with men applying 1 cc twice daily and women applying 1 cc once daily. Both treatments target hair regrowth and scalp health. Participants will be evaluated through clinical exams, trichoscopic hair assessments, and standardized scalp photos at the start, week 12, and week 24. Scalp biopsies will be taken at baseline and after three months to measure VEGF levels and, in some 2dDR users, to examine hair follicle and blood vessel changes. Safety will be monitored by tracking adverse events and scalp condition throughout the study period.

Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia